Prolia Treatment Planner | Osteoporosis | Amgen

Amgen is not responsible for the content of this third party website you are entering, and is not adopting such content into this correspondence.

Amgen is not responsible for the content of this third party website you are entering, and is not adopting such content into this correspondence.

Amgen is not responsible for the content of this third party website you are entering, and is not adopting such content into this correspondence.

Return to previous page Continue

PROLIA® TREATMENT PLANNER

Prolia® treatment is associated with continuous increases in BMD and sustained low incidence of vertebral, non-vertebral and hip fractures for up to 10 years of therapy.1
The Prolia® BMD calculator and treatment planner provides information on treatment targets for postmenopausal women at risk of fracture. The tool is based on 10 years of data from patients treated with Prolia®.
Click below to find out how long, on average, you should treat your patients with Prolia® to achieve a certain increase in BMD.
BMD Calculator
T-Score vs Time graph analysis and BMD score for proper prolia treatment.
The optimal total duration of anti-resorptive treatment for osteoporosis (including Prolia® and bisphosphonates) has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Prolia® on an individual patient basis, particularly after 5 or more years of use.2

References:
BMD: bone mineral density.
  1. Bone HG, et al. Lancet Diabetes Endocrinol. 2017;5:513–23.
  2. Prolia® (denosumab) Summary of Product Characteristics. Amgen. Last revised February 2020.

Home

SMPC

The information contained in this site is for healthcare professionals only

I am an EU-healthcare professional
I am a patient
I am a member of the public